These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 19372849)

  • 1. Issues in the design of trials comparing management strategies for heavily pretreated patients.
    Phillips AN; Cohen C; Lundgren JD
    Curr Opin HIV AIDS; 2006 Nov; 1(6):476-81. PubMed ID: 19372849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of selecting resistance mutations during treatment interruption.
    Martinez-Picado J; Wai Yan Tam L
    Curr Opin HIV AIDS; 2007 Jan; 2(1):6-13. PubMed ID: 19372859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trials for heavily pretreated patients: update in 2006.
    Katlama C; Ghosn J
    Curr Opin HIV AIDS; 2006 Nov; 1(6):495-501. PubMed ID: 19372852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation and management of early virological failure.
    Sax PE
    Curr Opin HIV AIDS; 2006 Sep; 1(5):409-16. PubMed ID: 19372840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring clinical trials of therapeutic vaccines in HIV infection: role of treatment interruption.
    Lederman MM; Penn-Nicholson A; Stone SF; Sieg SF; Rodriguez B
    Curr Opin HIV AIDS; 2007 Jan; 2(1):56-61. PubMed ID: 19372866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of the highly experienced patient.
    Hicks C
    Curr Opin HIV AIDS; 2006 Sep; 1(5):424-9. PubMed ID: 19372842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory issues in developing new HIV protease inhibitors: risks and benefits.
    Struble KA; Chan-Tack KM; Soon GG
    Curr Opin HIV AIDS; 2008 Nov; 3(6):676-80. PubMed ID: 19373041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical approach to drug resistance interpretation: expert advice.
    Clotet B; Paredes R
    Curr Opin HIV AIDS; 2007 Mar; 2(2):145-9. PubMed ID: 19372880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Partial treatment interruptions.
    Deeks SG; Martin JN
    Curr Opin HIV AIDS; 2007 Jan; 2(1):46-55. PubMed ID: 19372865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiretroviral resistance in different HIV-1 subtypes: impact on therapy outcomes and resistance testing interpretation.
    Camacho RJ; Vandamme AM
    Curr Opin HIV AIDS; 2007 Mar; 2(2):123-9. PubMed ID: 19372877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes for therapeutic vaccines trials.
    Taiwo B; Murphy R
    Curr Opin HIV AIDS; 2006 Nov; 1(6):502-6. PubMed ID: 19372853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
    Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship between genotypic sensitivity score and treatment outcomes in late stage HIV disease after supervised HAART.
    Castor D; Vlahov D; Hoover DR; Berkman A; Wu YF; Zeller B; Brechtl J; Hammer SM
    J Med Virol; 2009 Aug; 81(8):1323-35. PubMed ID: 19551816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Earlier initiation of antiretroviral therapy in treatment-naïve patients: implications of results of treatment interruption trials.
    Neaton JD; Grund B
    Curr Opin HIV AIDS; 2008 Mar; 3(2):112-7. PubMed ID: 19372951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment interruption in advanced failing patients.
    Staszewski S
    Curr Opin HIV AIDS; 2007 Jan; 2(1):39-45. PubMed ID: 19372864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment interruption for convenience, cost cutting and toxicity sparing.
    Nüesch R; Hirschel B
    Curr Opin HIV AIDS; 2007 Jan; 2(1):31-8. PubMed ID: 19372863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atherosclerotic vascular disease in HIV: it is not just antiretroviral therapy that hurts the heart!
    van Leuven SI; Sankatsing RR; Vermeulen JN; Kastelein JJ; Reiss P; Stroes ES
    Curr Opin HIV AIDS; 2007 Jul; 2(4):324-31. PubMed ID: 19372907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis virus immune restoration disease of the liver.
    Crane M; Matthews G; Lewin SR
    Curr Opin HIV AIDS; 2008 Jul; 3(4):446-52. PubMed ID: 19373004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug resistant mutations detected by genotypic drug resistance testing in patients failing therapy in clade C HIV-1 infected individuals from India.
    Kandathil AJ; Kannangai R; Verghese VP; Pulimood SA; Rupali P; Sridharan G; Grant P; Pillay D; Abraham OC
    Indian J Med Microbiol; 2009; 27(3):231-6. PubMed ID: 19584504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvements in antiretroviral therapy outcomes over calendar time.
    Boyd MA
    Curr Opin HIV AIDS; 2009 May; 4(3):194-9. PubMed ID: 19532050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.